[go: up one dir, main page]

WO2003033658A3 - Neutrokine-alpha and neutrokine-alpha splice variant - Google Patents

Neutrokine-alpha and neutrokine-alpha splice variant Download PDF

Info

Publication number
WO2003033658A3
WO2003033658A3 PCT/US2002/032910 US0232910W WO03033658A3 WO 2003033658 A3 WO2003033658 A3 WO 2003033658A3 US 0232910 W US0232910 W US 0232910W WO 03033658 A3 WO03033658 A3 WO 03033658A3
Authority
WO
WIPO (PCT)
Prior art keywords
neutrokine
alpha
methods
alphasv
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/032910
Other languages
French (fr)
Other versions
WO2003033658A2 (en
Inventor
Guo-Liang Yu
Reinhard Ebner
Jian Ni
Craig A Rosen
Michael W Laird
Stephen Ullrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to AU2002351495A priority Critical patent/AU2002351495A1/en
Priority to EP02786413A priority patent/EP1507793A4/en
Priority to CA002476675A priority patent/CA2476675A1/en
Publication of WO2003033658A2 publication Critical patent/WO2003033658A2/en
Anticipated expiration legal-status Critical
Publication of WO2003033658A3 publication Critical patent/WO2003033658A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.
PCT/US2002/032910 2001-10-17 2002-10-16 Neutrokine-alpha and neutrokine-alpha splice variant Ceased WO2003033658A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002351495A AU2002351495A1 (en) 2001-10-17 2002-10-16 Neutrokine-alpha and neutrokine-alpha splice variant
EP02786413A EP1507793A4 (en) 2001-10-17 2002-10-16 Neutrokine-alpha and neutrokine-alpha splice variant
CA002476675A CA2476675A1 (en) 2001-10-17 2002-10-16 Neutrokine-alpha and neutrokine-alpha splice variant

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US32950801P 2001-10-17 2001-10-17
US60/329,508 2001-10-17
US32974701P 2001-10-18 2001-10-18
US60/329,747 2001-10-18
US33083501P 2001-10-31 2001-10-31
US60/330,835 2001-10-31
US33147801P 2001-11-16 2001-11-16
US60/331,478 2001-11-16
US33672601P 2001-12-07 2001-12-07
US60/336,726 2001-12-07
US36854802P 2002-04-01 2002-04-01
US60/368,548 2002-04-01

Publications (2)

Publication Number Publication Date
WO2003033658A2 WO2003033658A2 (en) 2003-04-24
WO2003033658A3 true WO2003033658A3 (en) 2004-05-27

Family

ID=27559746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/032910 Ceased WO2003033658A2 (en) 2001-10-17 2002-10-16 Neutrokine-alpha and neutrokine-alpha splice variant

Country Status (4)

Country Link
EP (1) EP1507793A4 (en)
AU (1) AU2002351495A1 (en)
CA (1) CA2476675A1 (en)
WO (1) WO2003033658A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662395B2 (en) 2010-03-22 2017-05-30 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ES2609583T3 (en) 2000-06-16 2017-04-21 Human Genome Sciences, Inc. Antibodies that bind immunospecifically to BLyS
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
EP2332563A3 (en) 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
EP1952150B1 (en) 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
RS53168B (en) 2006-05-30 2014-06-30 Genentech Inc. Antibodies and Immunoconjugates and Their Use
ME02101B (en) 2007-10-30 2015-10-20 Genentech Inc Antibody purification by cation exchange chromatography
DK2848625T3 (en) 2008-08-14 2019-10-07 Genentech Inc Methods of removing a contaminant using ion exchange membrane chromatography with displacement of naturally occurring proteins
KR20110076918A (en) 2008-09-10 2011-07-06 제넨테크, 인크. Compositions and Methods for Preventing Oxidative Degradation of Proteins
CN102958538A (en) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 Compositions and methods useful for reducing the viscosity of protein-containing formulations
MX339666B (en) 2010-06-24 2016-06-03 Genentech Inc * Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations.
PL2794635T3 (en) 2011-12-22 2019-02-28 F.Hoffmann-La Roche Ag Ion exchange membrane chromatography
TWI856084B (en) 2019-04-01 2024-09-21 美商建南德克公司 Compositions and methods for stabilizing protein-containing formulations
CN110176272B (en) * 2019-04-18 2021-05-18 浙江工业大学 A protein disulfide bond prediction method based on multiple sequence alignment information

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU731553B2 (en) * 1996-10-25 2001-04-05 Human Genome Sciences, Inc. Neutrokine alpha
CA2419661A1 (en) * 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha and neutrokine-alpha splice variant

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
MACKAY ET AL.: "Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations", J. EXP. MED., vol. 190, no. 11, 6 December 1999 (1999-12-06), pages 1697 - 1710, XP000915435 *
MOORE ET AL.: "BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator", SCIENCE, vol. 285, 9 July 1999 (1999-07-09), pages 260 - 263, XP002142252 *
NARDELLI ET AL.: "B lymphocyte stimulator (BLyS): A therapeutic trichotomy for the treatment of B lymphocyte diseases", LEUKEMIA AND LYMPHOMA, vol. 43, no. 7, 2002, pages 1367 - 1373, XP002973536 *
SCHNEIDER ET AL.: "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth", J. EXP. MED., vol. 189, no. 11, 17 June 1999 (1999-06-17), pages 1747 - 1756, XP000915409 *
See also references of EP1507793A4 *
WARE ET AL.: "APRIL and BAFF connect autoimmunity and cancer", J. EXP. MEDICINE, vol. 192, no. 11, 2000, pages F35 - F37, XP002224635 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662395B2 (en) 2010-03-22 2017-05-30 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations

Also Published As

Publication number Publication date
WO2003033658A2 (en) 2003-04-24
EP1507793A2 (en) 2005-02-23
EP1507793A4 (en) 2006-02-01
AU2002351495A1 (en) 2003-04-28
CA2476675A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2007123765A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2002008284A3 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002000690A3 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2001055367A8 (en) Nucleic acids, proteins, and antibodies
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
WO2001055317A8 (en) Nucleic acids, proteins, and antibodies
WO2000053753A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
CY1109518T1 (en) Susceptor Activator of Growth Factors
WO2000053757A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2000053752A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2002026781A3 (en) Ige receptor antagonists
WO2001025433A3 (en) Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization
WO2001040464A8 (en) Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
AU5441200A (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2004020591A3 (en) Methods of use for novel human polypeptides encoded by polynucleotides
WO2002044366A3 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
WO2001055300A8 (en) Nucleic acids, proteins, and antibodies
WO2001000662A3 (en) The use of human fgh-8 polypeptides as neurotrophic agents
WO2004039952A3 (en) Methods of use for novel human polypeptides encoded by polynucleotides
WO2004046310A3 (en) Novel mouse polypeptides encoded by polynucleotides and methods of their use
WO2001055313A8 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2476675

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002786413

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002786413

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002786413

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)